Skip to content
  • Friday, 14 August 2026
  • 11:24 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
Laboratory Automation & Robotics

Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators

Lana Keisha May 23, 2026 0

The recent trajectory of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, casts a…

Read More
Laboratory Automation & Robotics

Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators

Lana Keisha May 16, 2026 0

The recent profile of Medvi by The New York Times earlier this month highlighted the company as a prime example…

Read More
Laboratory Automation & Robotics

Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception

Lana Keisha May 9, 2026 0

A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…

Read More
Walk-In Lab Testing Expands Patient Access and Autonomy in West VirginiaRestoring Mitochondrial Health Offers New Paradigm for Treating Chronic Nerve Pain and Diabetic NeuropathyArtificial Intelligence Struggles with Cognitive Control as Leading Models Falter in Classic Stroop Test ExperimentsQIAGEN Digital Insights Partners with NVIDIA to Revolutionize AI-Driven Drug Discovery
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ